Monte Rosa Therapeutics Inc GLUE

$10.66 +0.92 (9.45%)

Valuation

Market cap
830,949,000
Revenue TTM
$123,670,000
Net income TTM
$-38,630,000
PE ratio
0.00
Forward PE
—
Profit margin
-31.24%
Debt to equity
0.00

Trading

Volume
1,275,649
Avg volume
1,234,440
Day's range
$9.76 – $10.71
Shares out
85,313,000
Stochastic %K
6%
Beta
1.37
Analysts
Strong Sell
Price target
$28.12

Price

Company profile

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and sy...

Show more

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1a, IL-1ß and IL-18, as well as damage-associated molecular patterns. In addition, it develops CDK2 to treat multiple cancers, including ovarian, endometrial, gastric and breast. Further, its pipeline includes programs in immunology and inflammation indications, oncology, cardiovascular, metabolic, and genetic diseases. The company also develops QuEEN, a discovery engine, to enable its target-centric MGD discovery and development approach and its rational design of MGD product candidates. It has a strategic collaboration and licensing agreement with F. Hoffmann-La Roche Ltd.; and Novartis. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Phone
617 949 2643
Website
https://www.monterosatx.com
Address
321 Harrison Avenue, Suite 900, Boston, United States

Latest news

Stocktwits

gusm17 Oct 19, 6:38 PM
$CAPR hey friends - in a holding pattern here as we wait for Q3 earnings announcement to get clarity on a few key items (SAP 1.1 and any other early SAP being dismissed officially by fda), any official change of indication acceptance for current BLA from cardio to skeletal, and a commercial update if any with partnership involving NS. As we wait some other tickers I am invested in that are worth a serious look is $ABEO, $GLUE, and $CADL. Feel free to join the message boards on any of these as they show a lot of promise as we wait for this one to finalize…
1 replies
bullwink Oct 19, 6:23 PM
$GLUE oversold bounce or something real?
0 replies
Valueforall Oct 19, 4:28 PM
$GLUE boner@ alert!‼️
0 replies
Windy007 Oct 12, 1:15 AM
$GLUE 7:41 PM UBS assumed coverage of Monte Rosa Therapeutics with a Buy rating and price target of $19, up from $17. The firm believes the company's MRT-8102, a first-in-class oral NEK7 protein degrader in development for chronic inflammatory diseases, is differentiated versus both IL-6 antibodies and NLRP3 inhibitors. UBS expects investor appreciation of the atherosclerotic cardiovascular disease opportunity and MRT-8102's "differentiated profile" to increase over the next 12 months.
0 replies
LabPsycho Oct 8, 6:57 PM
$GLUE @Snackdaddy - I would like to see a plateau of a couple weeks and volume average daily under 500k for that period. Good luck
1 replies
Snackdaddy Oct 7, 8:17 PM
$GLUE from 10.75 to 10.17 is basically a red day. just sit on this and pick up maybe 9’s but could see $8 end of year
0 replies
Whiskeyunderthebed Oct 7, 7:59 PM
$GLUE I would start a position in the 9's here.
0 replies
MuchMillions Oct 6, 8:20 PM
$GLUE looks like its headed back to big $8 support will backup the truck in that area
1 replies